nodes	percent_of_prediction	percent_of_DWPC	metapath
Epinephrine—SLC22A5—Dactinomycin—testicular cancer	0.185	0.314	CbGbCtD
Epinephrine—SLC22A2—Vinblastine—testicular cancer	0.11	0.187	CbGbCtD
Epinephrine—SLC22A2—Cisplatin—testicular cancer	0.101	0.172	CbGbCtD
Epinephrine—CYP2C9—Ifosfamide—testicular cancer	0.0571	0.0969	CbGbCtD
Epinephrine—ADRA1B—vas deferens—testicular cancer	0.0555	0.532	CbGeAlD
Epinephrine—CYP3A4—Ifosfamide—testicular cancer	0.0332	0.0564	CbGbCtD
Epinephrine—CYP1A2—Etoposide—testicular cancer	0.0303	0.0514	CbGbCtD
Epinephrine—CYP2C9—Cisplatin—testicular cancer	0.0278	0.0471	CbGbCtD
Epinephrine—CYP3A4—Vinblastine—testicular cancer	0.0176	0.0299	CbGbCtD
Epinephrine—CYP3A4—Etoposide—testicular cancer	0.0159	0.0269	CbGbCtD
Epinephrine—CYP3A4—Doxorubicin—testicular cancer	0.0108	0.0184	CbGbCtD
Epinephrine—ADRBK1—embryo—testicular cancer	0.00757	0.0726	CbGeAlD
Epinephrine—Ischaemia—Vinblastine—testicular cancer	0.00736	0.029	CcSEcCtD
Epinephrine—Extravasation—Carboplatin—testicular cancer	0.00653	0.0258	CcSEcCtD
Epinephrine—Skin necrosis—Ifosfamide—testicular cancer	0.00555	0.0219	CcSEcCtD
Epinephrine—Rales—Bleomycin—testicular cancer	0.00553	0.0218	CcSEcCtD
Epinephrine—ADRBK1—gonad—testicular cancer	0.00514	0.0493	CbGeAlD
Epinephrine—Skin necrosis—Cisplatin—testicular cancer	0.00478	0.0189	CcSEcCtD
Epinephrine—Tachyarrhythmia—Epirubicin—testicular cancer	0.0047	0.0185	CcSEcCtD
Epinephrine—TNF—lymph node—testicular cancer	0.00468	0.0448	CbGeAlD
Epinephrine—Skin necrosis—Etoposide—testicular cancer	0.00438	0.0173	CcSEcCtD
Epinephrine—Tachyarrhythmia—Doxorubicin—testicular cancer	0.00435	0.0171	CcSEcCtD
Epinephrine—ADRB3—female gonad—testicular cancer	0.00427	0.041	CbGeAlD
Epinephrine—ADRBK1—female gonad—testicular cancer	0.00418	0.04	CbGeAlD
Epinephrine—Local reaction—Bleomycin—testicular cancer	0.0041	0.0162	CcSEcCtD
Epinephrine—Nephropathy—Ifosfamide—testicular cancer	0.00407	0.0161	CcSEcCtD
Epinephrine—ADRBK1—testis—testicular cancer	0.00371	0.0355	CbGeAlD
Epinephrine—Lactic acidosis—Epirubicin—testicular cancer	0.00352	0.0139	CcSEcCtD
Epinephrine—Lactic acidosis—Doxorubicin—testicular cancer	0.00325	0.0128	CcSEcCtD
Epinephrine—Nephropathy—Etoposide—testicular cancer	0.00322	0.0127	CcSEcCtD
Epinephrine—Extravasation—Vinblastine—testicular cancer	0.00308	0.0121	CcSEcCtD
Epinephrine—Necrosis—Dactinomycin—testicular cancer	0.0027	0.0106	CcSEcCtD
Epinephrine—ADRBK1—lymph node—testicular cancer	0.00269	0.0257	CbGeAlD
Epinephrine—Skin necrosis—Methotrexate—testicular cancer	0.00263	0.0103	CcSEcCtD
Epinephrine—Ventricular arrhythmia—Ifosfamide—testicular cancer	0.00262	0.0103	CcSEcCtD
Epinephrine—Extravasation—Bleomycin—testicular cancer	0.0026	0.0103	CcSEcCtD
Epinephrine—Ventricular fibrillation—Ifosfamide—testicular cancer	0.00253	0.00998	CcSEcCtD
Epinephrine—Necrosis—Ifosfamide—testicular cancer	0.00247	0.00974	CcSEcCtD
Epinephrine—Skin necrosis—Epirubicin—testicular cancer	0.00246	0.00969	CcSEcCtD
Epinephrine—Extravasation—Dactinomycin—testicular cancer	0.00243	0.00956	CcSEcCtD
Epinephrine—Hemiplegia—Epirubicin—testicular cancer	0.0024	0.00948	CcSEcCtD
Epinephrine—Skin necrosis—Doxorubicin—testicular cancer	0.00227	0.00896	CcSEcCtD
Epinephrine—ADRA2C—seminal vesicle—testicular cancer	0.00224	0.0215	CbGeAlD
Epinephrine—Rales—Methotrexate—testicular cancer	0.00224	0.00881	CcSEcCtD
Epinephrine—Hemiplegia—Doxorubicin—testicular cancer	0.00222	0.00877	CcSEcCtD
Epinephrine—Extravasation—Ifosfamide—testicular cancer	0.00222	0.00876	CcSEcCtD
Epinephrine—TNF—Canonical NF-kappaB pathway—BCL10—testicular cancer	0.00217	0.0411	CbGpPWpGaD
Epinephrine—Skin exfoliation—Bleomycin—testicular cancer	0.00217	0.00854	CcSEcCtD
Epinephrine—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00216	0.0409	CbGpPWpGaD
Epinephrine—SLC22A5—seminal vesicle—testicular cancer	0.00215	0.0206	CbGeAlD
Epinephrine—Ventricular extrasystoles—Ifosfamide—testicular cancer	0.00215	0.00846	CcSEcCtD
Epinephrine—Necrosis—Cisplatin—testicular cancer	0.00213	0.0084	CcSEcCtD
Epinephrine—Drug interaction—Ifosfamide—testicular cancer	0.00209	0.00824	CcSEcCtD
Epinephrine—Cerebrovascular accident—Vinblastine—testicular cancer	0.00199	0.00784	CcSEcCtD
Epinephrine—Necrosis—Etoposide—testicular cancer	0.00195	0.00769	CcSEcCtD
Epinephrine—Nephropathy—Methotrexate—testicular cancer	0.00193	0.0076	CcSEcCtD
Epinephrine—Extravasation—Cisplatin—testicular cancer	0.00192	0.00755	CcSEcCtD
Epinephrine—Tingling sensation—Etoposide—testicular cancer	0.00191	0.00751	CcSEcCtD
Epinephrine—Skin exfoliation—Ifosfamide—testicular cancer	0.00185	0.0073	CcSEcCtD
Epinephrine—Disorientation—Bleomycin—testicular cancer	0.00184	0.00726	CcSEcCtD
Epinephrine—ADRA2A—seminal vesicle—testicular cancer	0.00179	0.0171	CbGeAlD
Epinephrine—Extravasation—Etoposide—testicular cancer	0.00176	0.00692	CcSEcCtD
Epinephrine—Pulmonary oedema—Ifosfamide—testicular cancer	0.00173	0.0068	CcSEcCtD
Epinephrine—Cerebrovascular accident—Bleomycin—testicular cancer	0.00168	0.00663	CcSEcCtD
Epinephrine—ADRB3—G alpha (s) signalling events—INSL3—testicular cancer	0.00164	0.031	CbGpPWpGaD
Epinephrine—Skin exfoliation—Cisplatin—testicular cancer	0.0016	0.00629	CcSEcCtD
Epinephrine—Disorientation—Ifosfamide—testicular cancer	0.00157	0.0062	CcSEcCtD
Epinephrine—Local reaction—Epirubicin—testicular cancer	0.00155	0.00611	CcSEcCtD
Epinephrine—Acute coronary syndrome—Vinblastine—testicular cancer	0.00148	0.00584	CcSEcCtD
Epinephrine—Renal impairment—Ifosfamide—testicular cancer	0.00148	0.00583	CcSEcCtD
Epinephrine—Myocardial infarction—Vinblastine—testicular cancer	0.00147	0.00581	CcSEcCtD
Epinephrine—Hallucination—Chlorambucil—testicular cancer	0.00146	0.00577	CcSEcCtD
Epinephrine—Skin exfoliation—Etoposide—testicular cancer	0.00146	0.00576	CcSEcCtD
Epinephrine—Local reaction—Doxorubicin—testicular cancer	0.00143	0.00566	CcSEcCtD
Epinephrine—Psychotic disorder—Ifosfamide—testicular cancer	0.00137	0.00542	CcSEcCtD
Epinephrine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00136	0.0258	CbGpPWpGaD
Epinephrine—Haemoglobin—Vinblastine—testicular cancer	0.00136	0.00535	CcSEcCtD
Epinephrine—Haemorrhage—Vinblastine—testicular cancer	0.00135	0.00532	CcSEcCtD
Epinephrine—Hypoaesthesia—Vinblastine—testicular cancer	0.00134	0.00529	CcSEcCtD
Epinephrine—ADRA2C—female gonad—testicular cancer	0.00132	0.0126	CbGeAlD
Epinephrine—ADRA2A—gonad—testicular cancer	0.00129	0.0124	CbGeAlD
Epinephrine—Hypokalaemia—Ifosfamide—testicular cancer	0.00128	0.00505	CcSEcCtD
Epinephrine—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00127	0.024	CbGpPWpGaD
Epinephrine—SLC22A5—female gonad—testicular cancer	0.00126	0.0121	CbGeAlD
Epinephrine—Acute coronary syndrome—Bleomycin—testicular cancer	0.00125	0.00493	CcSEcCtD
Epinephrine—Myocardial infarction—Bleomycin—testicular cancer	0.00124	0.0049	CcSEcCtD
Epinephrine—Cerebrovascular accident—Cisplatin—testicular cancer	0.00124	0.00488	CcSEcCtD
Epinephrine—Agitation—Chlorambucil—testicular cancer	0.00118	0.00464	CcSEcCtD
Epinephrine—Necrosis—Methotrexate—testicular cancer	0.00117	0.00461	CcSEcCtD
Epinephrine—ADRA2C—testis—testicular cancer	0.00117	0.0112	CbGeAlD
Epinephrine—Ventricular arrhythmia—Epirubicin—testicular cancer	0.00116	0.00457	CcSEcCtD
Epinephrine—Haemoglobin—Bleomycin—testicular cancer	0.00115	0.00451	CcSEcCtD
Epinephrine—Haemorrhage—Bleomycin—testicular cancer	0.00114	0.00449	CcSEcCtD
Epinephrine—Hypoaesthesia—Bleomycin—testicular cancer	0.00113	0.00447	CcSEcCtD
Epinephrine—SLC22A5—testis—testicular cancer	0.00112	0.0107	CbGeAlD
Epinephrine—TNF—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.00112	0.0212	CbGpPWpGaD
Epinephrine—Hypokalaemia—Cisplatin—testicular cancer	0.0011	0.00435	CcSEcCtD
Epinephrine—Hyperglycaemia—Ifosfamide—testicular cancer	0.0011	0.00433	CcSEcCtD
Epinephrine—Necrosis—Epirubicin—testicular cancer	0.00109	0.00431	CcSEcCtD
Epinephrine—Ventricular arrhythmia—Doxorubicin—testicular cancer	0.00107	0.00423	CcSEcCtD
Epinephrine—Acute coronary syndrome—Ifosfamide—testicular cancer	0.00107	0.00422	CcSEcCtD
Epinephrine—Renal failure—Ifosfamide—testicular cancer	0.00107	0.0042	CcSEcCtD
Epinephrine—Myocardial infarction—Ifosfamide—testicular cancer	0.00106	0.00419	CcSEcCtD
Epinephrine—Flushing—Bleomycin—testicular cancer	0.00106	0.00417	CcSEcCtD
Epinephrine—Extravasation—Methotrexate—testicular cancer	0.00105	0.00414	CcSEcCtD
Epinephrine—ADRA2A—female gonad—testicular cancer	0.00105	0.0101	CbGeAlD
Epinephrine—Sweating increased—Cisplatin—testicular cancer	0.00102	0.00403	CcSEcCtD
Epinephrine—Hypertension—Vinblastine—testicular cancer	0.00101	0.004	CcSEcCtD
Epinephrine—Necrosis—Doxorubicin—testicular cancer	0.00101	0.00399	CcSEcCtD
Epinephrine—Erythema—Bleomycin—testicular cancer	0.000992	0.00391	CcSEcCtD
Epinephrine—Flushing—Dactinomycin—testicular cancer	0.000986	0.00389	CcSEcCtD
Epinephrine—Extravasation—Epirubicin—testicular cancer	0.000984	0.00388	CcSEcCtD
Epinephrine—SLC22A5—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000983	0.0186	CbGpPWpGaD
Epinephrine—Haemoglobin—Ifosfamide—testicular cancer	0.000979	0.00386	CcSEcCtD
Epinephrine—ADRB1—G alpha (s) signalling events—INSL3—testicular cancer	0.000974	0.0184	CbGpPWpGaD
Epinephrine—Haemorrhage—Ifosfamide—testicular cancer	0.000974	0.00384	CcSEcCtD
Epinephrine—Hallucination—Ifosfamide—testicular cancer	0.000969	0.00382	CcSEcCtD
Epinephrine—ADRB2—G alpha (s) signalling events—INSL3—testicular cancer	0.000953	0.018	CbGpPWpGaD
Epinephrine—Ventricular extrasystoles—Epirubicin—testicular cancer	0.00095	0.00375	CcSEcCtD
Epinephrine—Sweating increased—Etoposide—testicular cancer	0.000936	0.00369	CcSEcCtD
Epinephrine—ADRA2A—testis—testicular cancer	0.000932	0.00893	CbGeAlD
Epinephrine—Erythema—Dactinomycin—testicular cancer	0.000925	0.00365	CcSEcCtD
Epinephrine—Acute coronary syndrome—Cisplatin—testicular cancer	0.000922	0.00363	CcSEcCtD
Epinephrine—Renal failure—Cisplatin—testicular cancer	0.000919	0.00362	CcSEcCtD
Epinephrine—Myocardial infarction—Cisplatin—testicular cancer	0.000917	0.00361	CcSEcCtD
Epinephrine—Extravasation—Doxorubicin—testicular cancer	0.00091	0.00359	CcSEcCtD
Epinephrine—Flushing—Ifosfamide—testicular cancer	0.000904	0.00356	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.000903	0.00356	CcSEcCtD
Epinephrine—Ventricular extrasystoles—Doxorubicin—testicular cancer	0.000879	0.00347	CcSEcCtD
Epinephrine—Skin exfoliation—Methotrexate—testicular cancer	0.000876	0.00345	CcSEcCtD
Epinephrine—Arrhythmia—Ifosfamide—testicular cancer	0.00087	0.00343	CcSEcCtD
Epinephrine—Paraesthesia—Vinblastine—testicular cancer	0.000861	0.00339	CcSEcCtD
Epinephrine—Mental disorder—Ifosfamide—testicular cancer	0.000853	0.00336	CcSEcCtD
Epinephrine—Erythema—Ifosfamide—testicular cancer	0.000848	0.00334	CcSEcCtD
Epinephrine—ADRA2C—lymph node—testicular cancer	0.000847	0.00811	CbGeAlD
Epinephrine—ADRBK1—Phospholipase C-mediated cascade—FGFR3—testicular cancer	0.000845	0.016	CbGpPWpGaD
Epinephrine—Acute coronary syndrome—Etoposide—testicular cancer	0.000844	0.00333	CcSEcCtD
Epinephrine—Chest pain—Bleomycin—testicular cancer	0.000844	0.00333	CcSEcCtD
Epinephrine—Renal failure—Etoposide—testicular cancer	0.000842	0.00332	CcSEcCtD
Epinephrine—Myocardial infarction—Etoposide—testicular cancer	0.00084	0.00331	CcSEcCtD
Epinephrine—Skin exfoliation—Epirubicin—testicular cancer	0.00082	0.00323	CcSEcCtD
Epinephrine—Pulmonary oedema—Methotrexate—testicular cancer	0.000816	0.00322	CcSEcCtD
Epinephrine—SLC22A5—lymph node—testicular cancer	0.000811	0.00777	CbGeAlD
Epinephrine—ADRB3—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000782	0.0148	CbGpPWpGaD
Epinephrine—Flushing—Cisplatin—testicular cancer	0.000779	0.00307	CcSEcCtD
Epinephrine—Agitation—Ifosfamide—testicular cancer	0.000779	0.00307	CcSEcCtD
Epinephrine—Hypoaesthesia—Etoposide—testicular cancer	0.000765	0.00302	CcSEcCtD
Epinephrine—Pulmonary oedema—Epirubicin—testicular cancer	0.000764	0.00301	CcSEcCtD
Epinephrine—Skin exfoliation—Doxorubicin—testicular cancer	0.000758	0.00299	CcSEcCtD
Epinephrine—Arrhythmia—Cisplatin—testicular cancer	0.00075	0.00296	CcSEcCtD
Epinephrine—Palpitations—Ifosfamide—testicular cancer	0.000749	0.00295	CcSEcCtD
Epinephrine—Hypertension—Ifosfamide—testicular cancer	0.000732	0.00289	CcSEcCtD
Epinephrine—Erythema—Cisplatin—testicular cancer	0.000731	0.00288	CcSEcCtD
Epinephrine—Paraesthesia—Bleomycin—testicular cancer	0.000727	0.00287	CcSEcCtD
Epinephrine—Chest pain—Ifosfamide—testicular cancer	0.000722	0.00284	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.000717	0.00283	CcSEcCtD
Epinephrine—Flushing—Etoposide—testicular cancer	0.000714	0.00281	CcSEcCtD
Epinephrine—Pulmonary oedema—Doxorubicin—testicular cancer	0.000707	0.00279	CcSEcCtD
Epinephrine—Cerebrovascular accident—Methotrexate—testicular cancer	0.000679	0.00268	CcSEcCtD
Epinephrine—Nervous system disorder—Ifosfamide—testicular cancer	0.000678	0.00267	CcSEcCtD
Epinephrine—ADRA2A—lymph node—testicular cancer	0.000676	0.00647	CbGeAlD
Epinephrine—Skin disorder—Ifosfamide—testicular cancer	0.000672	0.00265	CcSEcCtD
Epinephrine—Hyperhidrosis—Ifosfamide—testicular cancer	0.000669	0.00264	CcSEcCtD
Epinephrine—Vomiting—Chlorambucil—testicular cancer	0.000665	0.00262	CcSEcCtD
Epinephrine—Renal impairment—Epirubicin—testicular cancer	0.000655	0.00258	CcSEcCtD
Epinephrine—TNF—Matrix Metalloproteinases—MMP2—testicular cancer	0.00064	0.0121	CbGpPWpGaD
Epinephrine—Hypoglycaemia—Epirubicin—testicular cancer	0.000639	0.00252	CcSEcCtD
Epinephrine—Cerebrovascular accident—Epirubicin—testicular cancer	0.000636	0.00251	CcSEcCtD
Epinephrine—Dizziness—Vinblastine—testicular cancer	0.000634	0.0025	CcSEcCtD
Epinephrine—Nausea—Chlorambucil—testicular cancer	0.000621	0.00245	CcSEcCtD
Epinephrine—Paraesthesia—Ifosfamide—testicular cancer	0.000621	0.00245	CcSEcCtD
Epinephrine—SLC22A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000618	0.0117	CbGpPWpGaD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.000618	0.00244	CcSEcCtD
Epinephrine—Somnolence—Ifosfamide—testicular cancer	0.000615	0.00242	CcSEcCtD
Epinephrine—Vomiting—Vinblastine—testicular cancer	0.000609	0.0024	CcSEcCtD
Epinephrine—TNF—amb2 Integrin signaling—MMP2—testicular cancer	0.000608	0.0115	CbGpPWpGaD
Epinephrine—Renal impairment—Doxorubicin—testicular cancer	0.000606	0.00239	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000597	0.00235	CcSEcCtD
Epinephrine—ADRB3—GPCR ligand binding—INSL3—testicular cancer	0.000596	0.0113	CbGpPWpGaD
Epinephrine—Hypoglycaemia—Doxorubicin—testicular cancer	0.000591	0.00233	CcSEcCtD
Epinephrine—Cerebrovascular accident—Doxorubicin—testicular cancer	0.000588	0.00232	CcSEcCtD
Epinephrine—Nervous system disorder—Cisplatin—testicular cancer	0.000585	0.00231	CcSEcCtD
Epinephrine—Tachycardia—Cisplatin—testicular cancer	0.000582	0.00229	CcSEcCtD
Epinephrine—Skin disorder—Cisplatin—testicular cancer	0.000579	0.00228	CcSEcCtD
Epinephrine—Hypertension—Etoposide—testicular cancer	0.000578	0.00228	CcSEcCtD
Epinephrine—Hyperhidrosis—Cisplatin—testicular cancer	0.000577	0.00227	CcSEcCtD
Epinephrine—SLC22A1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000576	0.0109	CbGpPWpGaD
Epinephrine—Chest pain—Etoposide—testicular cancer	0.00057	0.00225	CcSEcCtD
Epinephrine—Nausea—Vinblastine—testicular cancer	0.000569	0.00224	CcSEcCtD
Epinephrine—Hypokalaemia—Epirubicin—testicular cancer	0.000567	0.00224	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000566	0.00223	CcSEcCtD
Epinephrine—TNF—Developmental Biology—PRDM14—testicular cancer	0.000566	0.0107	CbGpPWpGaD
Epinephrine—Paraesthesia—Cisplatin—testicular cancer	0.000536	0.00211	CcSEcCtD
Epinephrine—Tachycardia—Etoposide—testicular cancer	0.000533	0.0021	CcSEcCtD
Epinephrine—Skin disorder—Etoposide—testicular cancer	0.000531	0.00209	CcSEcCtD
Epinephrine—Hyperhidrosis—Etoposide—testicular cancer	0.000528	0.00208	CcSEcCtD
Epinephrine—Hypokalaemia—Doxorubicin—testicular cancer	0.000525	0.00207	CcSEcCtD
Epinephrine—ADRBK1—Downstream signaling of activated FGFR—KITLG—testicular cancer	0.00052	0.00983	CbGpPWpGaD
Epinephrine—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000515	0.00203	CcSEcCtD
Epinephrine—Vomiting—Bleomycin—testicular cancer	0.000515	0.00203	CcSEcCtD
Epinephrine—Drowsiness—Methotrexate—testicular cancer	0.000513	0.00202	CcSEcCtD
Epinephrine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00051	0.00964	CbGpPWpGaD
Epinephrine—Renal failure—Methotrexate—testicular cancer	0.000504	0.00199	CcSEcCtD
Epinephrine—SLC22A5—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000499	0.00945	CbGpPWpGaD
Epinephrine—Sweating—Methotrexate—testicular cancer	0.000492	0.00194	CcSEcCtD
Epinephrine—Paraesthesia—Etoposide—testicular cancer	0.000491	0.00193	CcSEcCtD
Epinephrine—ADRBK1—Downstream signal transduction—KITLG—testicular cancer	0.000488	0.00924	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling by FGFR—KITLG—testicular cancer	0.000486	0.00919	CbGpPWpGaD
Epinephrine—Hyperglycaemia—Epirubicin—testicular cancer	0.000486	0.00192	CcSEcCtD
Epinephrine—Somnolence—Etoposide—testicular cancer	0.000486	0.00191	CcSEcCtD
Epinephrine—ADRBK1—Signaling by ERBB2—KITLG—testicular cancer	0.000484	0.00915	CbGpPWpGaD
Epinephrine—ADRBK1—DAP12 signaling—KITLG—testicular cancer	0.000481	0.0091	CbGpPWpGaD
Epinephrine—Nausea—Bleomycin—testicular cancer	0.000481	0.0019	CcSEcCtD
Epinephrine—Drowsiness—Epirubicin—testicular cancer	0.00048	0.00189	CcSEcCtD
Epinephrine—Vomiting—Dactinomycin—testicular cancer	0.00048	0.00189	CcSEcCtD
Epinephrine—Renal failure—Epirubicin—testicular cancer	0.000472	0.00186	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Etoposide—testicular cancer	0.000472	0.00186	CcSEcCtD
Epinephrine—ADRB1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000464	0.00878	CbGpPWpGaD
Epinephrine—Haemoglobin—Methotrexate—testicular cancer	0.000463	0.00183	CcSEcCtD
Epinephrine—Haemorrhage—Methotrexate—testicular cancer	0.000461	0.00182	CcSEcCtD
Epinephrine—Sweating—Epirubicin—testicular cancer	0.00046	0.00181	CcSEcCtD
Epinephrine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00046	0.0087	CbGpPWpGaD
Epinephrine—Dizziness—Ifosfamide—testicular cancer	0.000457	0.0018	CcSEcCtD
Epinephrine—ADRB2—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000454	0.00859	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling by FGFR in disease—KITLG—testicular cancer	0.000453	0.00857	CbGpPWpGaD
Epinephrine—ADRBK1—DAP12 interactions—KITLG—testicular cancer	0.000453	0.00857	CbGpPWpGaD
Epinephrine—ADRA1B—AMPK Signaling—STK11—testicular cancer	0.000451	0.00854	CbGpPWpGaD
Epinephrine—Hyperglycaemia—Doxorubicin—testicular cancer	0.00045	0.00177	CcSEcCtD
Epinephrine—ADRBK1—Signaling by EGFR—KITLG—testicular cancer	0.000449	0.00849	CbGpPWpGaD
Epinephrine—Nausea—Dactinomycin—testicular cancer	0.000448	0.00177	CcSEcCtD
Epinephrine—ADRBK1—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.000445	0.00841	CbGpPWpGaD
Epinephrine—Drowsiness—Doxorubicin—testicular cancer	0.000444	0.00175	CcSEcCtD
Epinephrine—ADRBK1—Signaling by PDGF—KITLG—testicular cancer	0.000443	0.00838	CbGpPWpGaD
Epinephrine—Vomiting—Ifosfamide—testicular cancer	0.00044	0.00173	CcSEcCtD
Epinephrine—Renal failure—Doxorubicin—testicular cancer	0.000437	0.00172	CcSEcCtD
Epinephrine—Haemoglobin—Epirubicin—testicular cancer	0.000433	0.00171	CcSEcCtD
Epinephrine—Haemorrhage—Epirubicin—testicular cancer	0.000431	0.0017	CcSEcCtD
Epinephrine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00043	0.00813	CbGpPWpGaD
Epinephrine—Hypoaesthesia—Epirubicin—testicular cancer	0.000429	0.00169	CcSEcCtD
Epinephrine—CYP2C9—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000428	0.00811	CbGpPWpGaD
Epinephrine—Sweating—Doxorubicin—testicular cancer	0.000426	0.00168	CcSEcCtD
Epinephrine—TNF—Angiopoietin receptor Tie2-mediated signaling—MMP2—testicular cancer	0.000425	0.00804	CbGpPWpGaD
Epinephrine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000423	0.008	CbGpPWpGaD
Epinephrine—ADRBK1—GPCR downstream signaling—INSL3—testicular cancer	0.000419	0.00793	CbGpPWpGaD
Epinephrine—Nausea—Ifosfamide—testicular cancer	0.000411	0.00162	CcSEcCtD
Epinephrine—Mental disorder—Methotrexate—testicular cancer	0.000404	0.00159	CcSEcCtD
Epinephrine—Erythema—Methotrexate—testicular cancer	0.000401	0.00158	CcSEcCtD
Epinephrine—ADRBK1—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000401	0.00759	CbGpPWpGaD
Epinephrine—Haemoglobin—Doxorubicin—testicular cancer	0.000401	0.00158	CcSEcCtD
Epinephrine—ADRA1A—AMPK Signaling—STK11—testicular cancer	0.000401	0.00758	CbGpPWpGaD
Epinephrine—Flushing—Epirubicin—testicular cancer	0.0004	0.00158	CcSEcCtD
Epinephrine—Haemorrhage—Doxorubicin—testicular cancer	0.000399	0.00157	CcSEcCtD
Epinephrine—Hypoaesthesia—Doxorubicin—testicular cancer	0.000397	0.00156	CcSEcCtD
Epinephrine—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000391	0.0074	CbGpPWpGaD
Epinephrine—ADRA1D—GPCR ligand binding—INSL3—testicular cancer	0.000388	0.00734	CbGpPWpGaD
Epinephrine—ADRBK1—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.000386	0.00731	CbGpPWpGaD
Epinephrine—Arrhythmia—Epirubicin—testicular cancer	0.000385	0.00152	CcSEcCtD
Epinephrine—ADRBK1—Signaling by GPCR—INSL3—testicular cancer	0.000381	0.0072	CbGpPWpGaD
Epinephrine—Vomiting—Cisplatin—testicular cancer	0.000379	0.00149	CcSEcCtD
Epinephrine—Mental disorder—Epirubicin—testicular cancer	0.000378	0.00149	CcSEcCtD
Epinephrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000376	0.00711	CbGpPWpGaD
Epinephrine—Erythema—Epirubicin—testicular cancer	0.000375	0.00148	CcSEcCtD
Epinephrine—Flushing—Doxorubicin—testicular cancer	0.00037	0.00146	CcSEcCtD
Epinephrine—Tension—Epirubicin—testicular cancer	0.000368	0.00145	CcSEcCtD
Epinephrine—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000366	0.00693	CbGpPWpGaD
Epinephrine—Nervousness—Epirubicin—testicular cancer	0.000364	0.00144	CcSEcCtD
Epinephrine—ADRBK1—Downstream signal transduction—FGFR3—testicular cancer	0.000363	0.00687	CbGpPWpGaD
Epinephrine—Dizziness—Etoposide—testicular cancer	0.000361	0.00142	CcSEcCtD
Epinephrine—ADRBK1—Signaling by FGFR—FGFR3—testicular cancer	0.000361	0.00683	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling by ERBB2—FGFR3—testicular cancer	0.000359	0.0068	CbGpPWpGaD
Epinephrine—TNF—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000358	0.00677	CbGpPWpGaD
Epinephrine—ADRBK1—DAP12 signaling—FGFR3—testicular cancer	0.000358	0.00677	CbGpPWpGaD
Epinephrine—Arrhythmia—Doxorubicin—testicular cancer	0.000356	0.0014	CcSEcCtD
Epinephrine—ADRBK1—Downstream signaling of activated FGFR—KIT—testicular cancer	0.000355	0.00671	CbGpPWpGaD
Epinephrine—Nausea—Cisplatin—testicular cancer	0.000354	0.0014	CcSEcCtD
Epinephrine—ADRB1—GPCR ligand binding—INSL3—testicular cancer	0.000354	0.00669	CbGpPWpGaD
Epinephrine—ADRA2B—GPCR ligand binding—INSL3—testicular cancer	0.00035	0.00663	CbGpPWpGaD
Epinephrine—Mental disorder—Doxorubicin—testicular cancer	0.000349	0.00138	CcSEcCtD
Epinephrine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000349	0.0066	CbGpPWpGaD
Epinephrine—Vomiting—Etoposide—testicular cancer	0.000347	0.00137	CcSEcCtD
Epinephrine—Erythema—Doxorubicin—testicular cancer	0.000347	0.00137	CcSEcCtD
Epinephrine—ADRB2—GPCR ligand binding—INSL3—testicular cancer	0.000346	0.00654	CbGpPWpGaD
Epinephrine—Agitation—Epirubicin—testicular cancer	0.000345	0.00136	CcSEcCtD
Epinephrine—Chest pain—Methotrexate—testicular cancer	0.000341	0.00135	CcSEcCtD
Epinephrine—Tension—Doxorubicin—testicular cancer	0.000341	0.00134	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000339	0.00134	CcSEcCtD
Epinephrine—Nervousness—Doxorubicin—testicular cancer	0.000337	0.00133	CcSEcCtD
Epinephrine—ADRB3—GPCR downstream signaling—INSL3—testicular cancer	0.000337	0.00637	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000336	0.00637	CbGpPWpGaD
Epinephrine—ADRBK1—DAP12 interactions—FGFR3—testicular cancer	0.000336	0.00637	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling by EGFR—FGFR3—testicular cancer	0.000333	0.00631	CbGpPWpGaD
Epinephrine—ADRBK1—Downstream signal transduction—KIT—testicular cancer	0.000333	0.0063	CbGpPWpGaD
Epinephrine—Palpitations—Epirubicin—testicular cancer	0.000332	0.00131	CcSEcCtD
Epinephrine—ADRBK1—Signaling by FGFR—KIT—testicular cancer	0.000332	0.00627	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.00033	0.00625	CbGpPWpGaD
Epinephrine—ADRA2C—Integration of energy metabolism—STK11—testicular cancer	0.00033	0.00625	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling by ERBB2—KIT—testicular cancer	0.00033	0.00624	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling by PDGF—FGFR3—testicular cancer	0.000329	0.00623	CbGpPWpGaD
Epinephrine—ADRBK1—DAP12 signaling—KIT—testicular cancer	0.000328	0.00621	CbGpPWpGaD
Epinephrine—ADRA2C—GPCR ligand binding—INSL3—testicular cancer	0.000327	0.00619	CbGpPWpGaD
Epinephrine—Nausea—Etoposide—testicular cancer	0.000325	0.00128	CcSEcCtD
Epinephrine—Hypertension—Epirubicin—testicular cancer	0.000324	0.00128	CcSEcCtD
Epinephrine—ADRA1B—GPCR ligand binding—INSL3—testicular cancer	0.000322	0.00609	CbGpPWpGaD
Epinephrine—Nervous system disorder—Methotrexate—testicular cancer	0.000321	0.00127	CcSEcCtD
Epinephrine—Chest pain—Epirubicin—testicular cancer	0.000319	0.00126	CcSEcCtD
Epinephrine—Agitation—Doxorubicin—testicular cancer	0.000319	0.00126	CcSEcCtD
Epinephrine—Skin disorder—Methotrexate—testicular cancer	0.000318	0.00125	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000317	0.00125	CcSEcCtD
Epinephrine—Hyperhidrosis—Methotrexate—testicular cancer	0.000316	0.00125	CcSEcCtD
Epinephrine—SLC22A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000314	0.00595	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling by FGFR in disease—KIT—testicular cancer	0.000309	0.00584	CbGpPWpGaD
Epinephrine—ADRBK1—DAP12 interactions—KIT—testicular cancer	0.000309	0.00584	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling by NGF—KITLG—testicular cancer	0.000308	0.00583	CbGpPWpGaD
Epinephrine—Palpitations—Doxorubicin—testicular cancer	0.000307	0.00121	CcSEcCtD
Epinephrine—ADRBK1—Signaling by EGFR—KIT—testicular cancer	0.000306	0.00579	CbGpPWpGaD
Epinephrine—ADRB3—Signaling by GPCR—INSL3—testicular cancer	0.000306	0.00578	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling by EGFR in Cancer—KIT—testicular cancer	0.000303	0.00574	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling by PDGF—KIT—testicular cancer	0.000302	0.00572	CbGpPWpGaD
Epinephrine—Nervous system disorder—Epirubicin—testicular cancer	0.0003	0.00118	CcSEcCtD
Epinephrine—Hypertension—Doxorubicin—testicular cancer	0.0003	0.00118	CcSEcCtD
Epinephrine—Tachycardia—Epirubicin—testicular cancer	0.000299	0.00118	CcSEcCtD
Epinephrine—ADRBK1—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000298	0.00564	CbGpPWpGaD
Epinephrine—Skin disorder—Epirubicin—testicular cancer	0.000297	0.00117	CcSEcCtD
Epinephrine—Hyperhidrosis—Epirubicin—testicular cancer	0.000296	0.00117	CcSEcCtD
Epinephrine—Insomnia—Methotrexate—testicular cancer	0.000296	0.00117	CcSEcCtD
Epinephrine—Chest pain—Doxorubicin—testicular cancer	0.000296	0.00117	CcSEcCtD
Epinephrine—Paraesthesia—Methotrexate—testicular cancer	0.000294	0.00116	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000294	0.00116	CcSEcCtD
Epinephrine—SLC22A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000293	0.00554	CbGpPWpGaD
Epinephrine—ADRBK1—Innate Immune System—BCL10—testicular cancer	0.000292	0.00552	CbGpPWpGaD
Epinephrine—Somnolence—Methotrexate—testicular cancer	0.000291	0.00115	CcSEcCtD
Epinephrine—ADRA1A—GPCR ligand binding—INSL3—testicular cancer	0.000286	0.00541	CbGpPWpGaD
Epinephrine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000283	0.00111	CcSEcCtD
Epinephrine—Nervous system disorder—Doxorubicin—testicular cancer	0.000278	0.0011	CcSEcCtD
Epinephrine—Insomnia—Epirubicin—testicular cancer	0.000277	0.00109	CcSEcCtD
Epinephrine—Tachycardia—Doxorubicin—testicular cancer	0.000277	0.00109	CcSEcCtD
Epinephrine—Skin disorder—Doxorubicin—testicular cancer	0.000275	0.00109	CcSEcCtD
Epinephrine—Paraesthesia—Epirubicin—testicular cancer	0.000275	0.00108	CcSEcCtD
Epinephrine—Hyperhidrosis—Doxorubicin—testicular cancer	0.000274	0.00108	CcSEcCtD
Epinephrine—ADRBK1—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000274	0.00518	CbGpPWpGaD
Epinephrine—Somnolence—Epirubicin—testicular cancer	0.000272	0.00107	CcSEcCtD
Epinephrine—ADRA2A—Integration of energy metabolism—STK11—testicular cancer	0.000268	0.00507	CbGpPWpGaD
Epinephrine—ADRA1B—LPA receptor mediated events—MMP2—testicular cancer	0.000268	0.00507	CbGpPWpGaD
Epinephrine—ADRA2A—GPCR ligand binding—INSL3—testicular cancer	0.000266	0.00503	CbGpPWpGaD
Epinephrine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000264	0.00104	CcSEcCtD
Epinephrine—TNF—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.00026	0.00492	CbGpPWpGaD
Epinephrine—Insomnia—Doxorubicin—testicular cancer	0.000256	0.00101	CcSEcCtD
Epinephrine—Paraesthesia—Doxorubicin—testicular cancer	0.000254	0.001	CcSEcCtD
Epinephrine—Somnolence—Doxorubicin—testicular cancer	0.000252	0.000993	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000245	0.000965	CcSEcCtD
Epinephrine—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	0.000233	0.00441	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling by NGF—FGFR3—testicular cancer	0.000229	0.00434	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—INSL3—testicular cancer	0.000225	0.00426	CbGpPWpGaD
Epinephrine—ADRA1D—GPCR downstream signaling—INSL3—testicular cancer	0.000219	0.00415	CbGpPWpGaD
Epinephrine—Dizziness—Methotrexate—testicular cancer	0.000216	0.000853	CcSEcCtD
Epinephrine—ADRBK1—Signaling by NGF—KIT—testicular cancer	0.00021	0.00398	CbGpPWpGaD
Epinephrine—Vomiting—Methotrexate—testicular cancer	0.000208	0.00082	CcSEcCtD
Epinephrine—Dizziness—Epirubicin—testicular cancer	0.000203	0.000798	CcSEcCtD
Epinephrine—ADRB1—GPCR downstream signaling—INSL3—testicular cancer	0.0002	0.00378	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling by GPCR—INSL3—testicular cancer	0.000199	0.00377	CbGpPWpGaD
Epinephrine—ADRA2B—GPCR downstream signaling—INSL3—testicular cancer	0.000198	0.00375	CbGpPWpGaD
Epinephrine—ADRB2—GPCR downstream signaling—INSL3—testicular cancer	0.000195	0.0037	CbGpPWpGaD
Epinephrine—Vomiting—Epirubicin—testicular cancer	0.000195	0.000768	CcSEcCtD
Epinephrine—Nausea—Methotrexate—testicular cancer	0.000194	0.000766	CcSEcCtD
Epinephrine—Dizziness—Doxorubicin—testicular cancer	0.000187	0.000739	CcSEcCtD
Epinephrine—ADRA2C—GPCR downstream signaling—INSL3—testicular cancer	0.000185	0.0035	CbGpPWpGaD
Epinephrine—PAH—Metabolism—HPGDS—testicular cancer	0.000185	0.0035	CbGpPWpGaD
Epinephrine—ADRA1B—GPCR downstream signaling—INSL3—testicular cancer	0.000182	0.00344	CbGpPWpGaD
Epinephrine—Nausea—Epirubicin—testicular cancer	0.000182	0.000717	CcSEcCtD
Epinephrine—ADRB1—Signaling by GPCR—INSL3—testicular cancer	0.000181	0.00343	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—INSL3—testicular cancer	0.000181	0.00342	CbGpPWpGaD
Epinephrine—Vomiting—Doxorubicin—testicular cancer	0.00018	0.00071	CcSEcCtD
Epinephrine—ADRA2B—Signaling by GPCR—INSL3—testicular cancer	0.00018	0.0034	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—INSL3—testicular cancer	0.000177	0.00336	CbGpPWpGaD
Epinephrine—ADRBK1—Innate Immune System—KITLG—testicular cancer	0.000176	0.00333	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—BCL10—testicular cancer	0.00017	0.00321	CbGpPWpGaD
Epinephrine—Nausea—Doxorubicin—testicular cancer	0.000168	0.000664	CcSEcCtD
Epinephrine—ADRA2C—Signaling by GPCR—INSL3—testicular cancer	0.000168	0.00318	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—INSL3—testicular cancer	0.000165	0.00313	CbGpPWpGaD
Epinephrine—ADRA1A—GPCR downstream signaling—INSL3—testicular cancer	0.000162	0.00306	CbGpPWpGaD
Epinephrine—PAH—Disease—H2AFZ—testicular cancer	0.000161	0.00305	CbGpPWpGaD
Epinephrine—CYP2C9—Biological oxidations—HPGDS—testicular cancer	0.000159	0.00302	CbGpPWpGaD
Epinephrine—ADRA2A—GPCR downstream signaling—INSL3—testicular cancer	0.00015	0.00284	CbGpPWpGaD
Epinephrine—PAH—Disease—KITLG—testicular cancer	0.000148	0.00281	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—INSL3—testicular cancer	0.000147	0.00278	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—INSL3—testicular cancer	0.000136	0.00258	CbGpPWpGaD
Epinephrine—CYP1A2—Biological oxidations—HPGDS—testicular cancer	0.000136	0.00258	CbGpPWpGaD
Epinephrine—PAH—Metabolism—STK11—testicular cancer	0.000134	0.00254	CbGpPWpGaD
Epinephrine—ADRBK1—Innate Immune System—FGFR3—testicular cancer	0.000131	0.00247	CbGpPWpGaD
Epinephrine—ADRBK1—Innate Immune System—KIT—testicular cancer	0.00012	0.00227	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—INSL3—testicular cancer	0.000118	0.00223	CbGpPWpGaD
Epinephrine—PAH—Disease—FGFR3—testicular cancer	0.00011	0.00209	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—INSL3—testicular cancer	0.000107	0.00203	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—INSL3—testicular cancer	0.000106	0.00201	CbGpPWpGaD
Epinephrine—CYP3A4—Biological oxidations—HPGDS—testicular cancer	0.000105	0.00199	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—INSL3—testicular cancer	0.000105	0.00198	CbGpPWpGaD
Epinephrine—ADRBK1—Disease—H2AFZ—testicular cancer	0.000103	0.00195	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—KITLG—testicular cancer	0.000102	0.00194	CbGpPWpGaD
Epinephrine—PAH—Disease—KIT—testicular cancer	0.000101	0.00192	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—INSL3—testicular cancer	9.92e-05	0.00188	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—INSL3—testicular cancer	9.76e-05	0.00185	CbGpPWpGaD
Epinephrine—ADRBK1—Disease—KITLG—testicular cancer	9.46e-05	0.00179	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—INSL3—testicular cancer	8.67e-05	0.00164	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—INSL3—testicular cancer	8.06e-05	0.00152	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—FGFR3—testicular cancer	7.61e-05	0.00144	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—H2AFZ—testicular cancer	7.2e-05	0.00136	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—STK11—testicular cancer	7.16e-05	0.00135	CbGpPWpGaD
Epinephrine—ADRBK1—Disease—FGFR3—testicular cancer	7.03e-05	0.00133	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—KIT—testicular cancer	6.99e-05	0.00132	CbGpPWpGaD
Epinephrine—TNF—Developmental Biology—MMP2—testicular cancer	6.8e-05	0.00129	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—KITLG—testicular cancer	6.62e-05	0.00125	CbGpPWpGaD
Epinephrine—ADRBK1—Disease—KIT—testicular cancer	6.45e-05	0.00122	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	6.12e-05	0.00116	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—H2AFZ—testicular cancer	5.78e-05	0.00109	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—STK11—testicular cancer	5.75e-05	0.00109	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—HPGDS—testicular cancer	5.34e-05	0.00101	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—KITLG—testicular cancer	5.32e-05	0.00101	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	5.23e-05	0.00099	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—HPGDS—testicular cancer	5.2e-05	0.000983	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—HPGDS—testicular cancer	4.98e-05	0.000942	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—FGFR3—testicular cancer	4.92e-05	0.000931	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—KIT—testicular cancer	4.52e-05	0.000855	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—HPGDS—testicular cancer	4.22e-05	0.000799	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—FGFR3—testicular cancer	3.95e-05	0.000748	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—STK11—testicular cancer	3.88e-05	0.000734	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—STK11—testicular cancer	3.78e-05	0.000714	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—H2AFZ—testicular cancer	3.77e-05	0.000712	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—STK11—testicular cancer	3.74e-05	0.000708	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—KIT—testicular cancer	3.63e-05	0.000687	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—STK11—testicular cancer	3.62e-05	0.000685	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—KITLG—testicular cancer	3.46e-05	0.000655	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—H2AFZ—testicular cancer	3.43e-05	0.000649	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—STK11—testicular cancer	3.41e-05	0.000645	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—H2AFZ—testicular cancer	3.4e-05	0.000643	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—STK11—testicular cancer	3.38e-05	0.00064	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—H2AFZ—testicular cancer	3.36e-05	0.000635	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—STK11—testicular cancer	3.34e-05	0.000631	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—H2AFZ—testicular cancer	3.18e-05	0.000601	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—STK11—testicular cancer	3.16e-05	0.000597	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—KITLG—testicular cancer	3.16e-05	0.000597	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—KITLG—testicular cancer	3.13e-05	0.000592	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—H2AFZ—testicular cancer	3.13e-05	0.000591	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—STK11—testicular cancer	3.11e-05	0.000588	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—KITLG—testicular cancer	3.09e-05	0.000584	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—STK11—testicular cancer	3.07e-05	0.00058	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—KITLG—testicular cancer	2.92e-05	0.000553	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—KITLG—testicular cancer	2.88e-05	0.000544	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—H2AFZ—testicular cancer	2.78e-05	0.000525	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—STK11—testicular cancer	2.76e-05	0.000522	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—HPGDS—testicular cancer	2.73e-05	0.000516	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—H2AFZ—testicular cancer	2.58e-05	0.000488	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—FGFR3—testicular cancer	2.57e-05	0.000487	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—STK11—testicular cancer	2.56e-05	0.000485	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—KITLG—testicular cancer	2.55e-05	0.000483	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—KITLG—testicular cancer	2.37e-05	0.000449	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—KIT—testicular cancer	2.36e-05	0.000447	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—FGFR3—testicular cancer	2.35e-05	0.000444	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—HPGDS—testicular cancer	2.33e-05	0.000441	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—FGFR3—testicular cancer	2.32e-05	0.00044	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—FGFR3—testicular cancer	2.29e-05	0.000434	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—FGFR3—testicular cancer	2.17e-05	0.000411	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—KIT—testicular cancer	2.15e-05	0.000407	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—FGFR3—testicular cancer	2.14e-05	0.000404	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—KIT—testicular cancer	2.13e-05	0.000404	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—KIT—testicular cancer	2.11e-05	0.000399	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—KIT—testicular cancer	1.99e-05	0.000377	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—STK11—testicular cancer	1.98e-05	0.000375	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—KIT—testicular cancer	1.96e-05	0.000371	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—FGFR3—testicular cancer	1.9e-05	0.000359	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—HPGDS—testicular cancer	1.8e-05	0.00034	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—FGFR3—testicular cancer	1.76e-05	0.000334	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—KIT—testicular cancer	1.74e-05	0.00033	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—STK11—testicular cancer	1.69e-05	0.00032	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—KIT—testicular cancer	1.62e-05	0.000306	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—STK11—testicular cancer	1.31e-05	0.000247	CbGpPWpGaD
